Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.95
Wellgistics Health, Inc. incurred convertible notes of up to $3,125,000 in aggregate principal amount with certain investors at 0% except in the event of an event of default, in which case, the default intere maturing on (a) the six (6) month anniversary of the date of issuance of the Notes, or (b) the date of closing of the next issuance and sale of capital stock of the Comp.
- Instrument
- convertible notes
- Principal
- up to $3,125,000 in aggregate principal amount
- Counterparty
- certain investors
- Rate
- 0% except in the event of an event of default, in which case, the default intere
- Maturity
- on (a) the six (6) month anniversary of the date of issuance of the Notes, or (b) the date of closing of the next issuance and sale of capital stock of the Comp
- Event
- incurrence
Exact text from the filing
On January 5, 2026, Wellgistics Health, Inc. (the “Company”), entered into a note purchase agreement (the “Note Purchase Agreement”) with certain investors (the “Investors”) whereby the Company agreed to issue and sell to the Investors in a private offering up to $3,125,000 in aggregate principal amount (the “Aggregate Principal Amount”) of convertible promissory notes (the “Notes”) (the “Offering”).
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.95
Wellgistics Health, Inc. issued up to $3,125,000 in aggregate principal amount of convertible promissory notes of convertible note to certain investors for aggregate purchase price of $2,500,000, reflecting a 20% original issue discount.
- Security
- convertible note
- Shares
- up to $3,125,000 in aggregate principal amount of convertible promissory notes
- Purchaser
- certain investors
- Consideration
- aggregate purchase price of $2,500,000, reflecting a 20% original issue discount
Exact text from the filing
amount (the “Aggregate Principal Amount”) of convertible promissory notes (the “Notes”) (the “Offering”). The aggregate purchase price payable by all Investors for the Notes is $2,500,000, reflecting a 20% original issue discount. All principal and interest on the outstanding principal will accrue and, unless converted earlier as set forth below, be due and
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Wellgistics Health, Inc. entered into Placement Agency Agreement with Dawson James Securities, Inc. (the “Placement Agent”) (effective 2026-01-05).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Dawson James Securities, Inc. (the “Placement Agent”)
- Effective
- 2026-01-05
Exact text from the filing
On January 5, 2026, in connection with the Offering, the Company entered into a placement agency agreement, a copy of which is filed as Exhibit 10.3 to this Current Report on Form 8-K (the “Placement Agency Agreement”) with Dawson James Securities, Inc. (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as the Company’s placement agent in connection with the Offering.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Wellgistics Health, Inc. entered into Note Purchase Agreement with certain investors (the "Investors") valued at up to $3,125,000 in aggregate principal amount (effective 2026-01-05).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- certain investors (the "Investors")
- Value
- up to $3,125,000 in aggregate principal amount
- Effective
- 2026-01-05
Exact text from the filing
On January 5, 2026, Wellgistics Health, Inc. (the “Company”), entered into a note purchase agreement (the “Note Purchase Agreement”) with certain investors (the “Investors”) whereby the Company agreed to issue and sell to the Investors in a private offering up to $3,125,000 in aggregate principal amount (the “Aggregate Principal Amount”) of convertible promissory notes (the “Notes”) (the “Offering”).
View on SEC.gov